We are proud to announce that on 28 April 2026, SyVento BioTech officially received the Certificate of GMP Compliance of a Manufacturer, marking one of the most significant milestones in the company’s history. The certificate was granted following an inspection conducted under the national inspection programme, in connection with manufacturing authorisation no. 285/0662/25, and carried out in accordance with Article 61(1) of Regulation (EU) No 536/2024.
Receiving Good Manufacturing Practice (GMP) Manufacturing Authorisation has been an exceptionally long‑awaited moment for SyVento BioTech and stands as a true testament to the dedication, expertise, and close collaboration of our employees and partners. This collective commitment and shared vision have enabled us to reach a milestone that now opens new possibilities for innovation and growth.
The GMP certification is not only a major step forward for SyVento BioTech, but also for Poland. We are currently the only company in the country able to meaningfully support the development of RNA‑based therapies and lipid nanoparticle (LNP) technologies, while offering a broad CDMO service portfolio, including manufacturing of injectable drug products and fill & finish.
We would like to express our sincere gratitude to everyone who contributed to this success, and we look ahead with great ambition and determination, driven by our shared goal to shape the future of medicine.
